{"name":"Iltoo Pharma","slug":"iltoo-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxPSXIwNlY4QXpwM1pSTThkajRZenBRWVFPMkVhYW45TkNVX2F3bUlFRFkyQmNTaHpPYy1xdlZTWXk2bHlJNkdNY3ZtR0hzb0NDbzFfMzBlRG5fUnhVSkxYU2lvNFpXM0FIWDNKWk9xWW1wR19qTFJUZExFOXZrdTVHbnVzNC1EemlkWnE2WXl0b0tnS1d5bjRsSWR3cVh4cnZ2Q2dRVVo3SXNLMC11dmJzWjRDeG1GY0FHdGtFNVVTcFNKZ09uNDVZWDl3RlVqdk5lSVJiSkdfbUY3bUUxQlJZLVhQaXZ2dzZLTzFWaXZwbkpCM2U4OThFU1JMSElnWE1ZTnc?oc=5","date":"2026-04-01","type":"trial","source":"Barchart.com","summary":"Systemic Sclerosis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com","headline":"Systemic Sclerosis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxQczFaMW1rekJaNmo3bVNnMEJQUmJkSWxPa0tQYmt0T2I3TW5CY1F3VmQ0eWpKcjZDOWVpMnNFQjFkd01ZSkQwRTI4TDRjTF9KMS1VRFNoODBObDE3elJaVTVZN1lvRmMtVl9COU1LX3dZRFlCSkdfcDYxVzNza1dWSU1ZbUoyUlRyZUt6TVZLVTRHYjhhYnozNG91TzhpTUxoVVhUNjlER0huVGFSV3ctb2gtMWE1NU4wSEhBWkJLbkk1amtmbFhVS09UcVF6QXNQR1dFQmczRDhZZENrUVJRVlVPVDNLaDVqZkJ3R2Vvbi1EYjk2R1dyVU1VQkctaTBKM0EycmZPNXVRQnJ3OWpzVFRrUW0wVWxFdWdqLUhhUUtyV0lsSUdHVmh4MS1XMUJTLS02SzJUWl8xdmYwSDE4?oc=5","date":"2026-04-01","type":"regulatory","source":"GlobeNewswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline - GlobeNewswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxON3haaElHU09WM2UxVFAtWGQyRUtONkJKSURwc1E0bWVjVnRTVTRTVklWSFBiZURWLWgtQWhEcGFBNmZLM0FhTFFZeE5tWE90dnRVRzk2bVlVVFEzS3dtX3c5T3Y3allKd1E2UEhUbzJGdnk0SlR4Z2hsTkxHTy1XNTljamJJcnJ2WG5YVUd2RS1pWlE4aHp0WFR2TGU1WGcxa3Fabk0walIxdGZCXzg3amhpTkpJSm12ajR5akpkTVpuc1RaSUZKek1yZEc1WVFGWVkwSnZBX1Q2T0EtUmlaREM4eVl4T3RoRE1iZmpkTTk0VUM2NXRhdkdxc3ZNOEJMTVc3Zk5HcUp0bzdESU42OFN0cmQ1ZDFYX0JzdVZBV0gtZjY0cDQzUl9sQ01fSllFcjhhRA?oc=5","date":"2025-07-10","type":"trial","source":"GlobeNewswire","summary":"Interleukin-2 Inhibitors Clinical Trial Pipeline - GlobeNewswire","headline":"Interleukin-2 Inhibitors Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPMGhPdGxVQ2ZhVEN3MkFUXy1rb0VSR3Y3Y3FuWXhzVWdMVmVkdkpHZnZXMWRHcnAyeEVUTVN0X09tRDA3bVdtR2M4M1lVNFo5UXNWWjEzRkNoSjBJS0llaXZNV0VSaEFqOFpvcjFoa0paYkNCZi1HdGR4OHBVY2Y4eGFTNWNLUzFkaHgydjNSRkxiNDdsU2c1WWl1elI0aUNfRmh2c0xYMENfZ0oteDk5c1hRY0swVjVkMjJaMF93eGpSaTBnVFJETjNxMFpSOUx0c1Z5N0VBdlFjYzlpNnhrcGxBbFAzZ20ycVE?oc=5","date":"2025-04-15","type":"pipeline","source":"prnewswire.com","summary":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight - prnewswire.com","headline":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-03-27","type":"pipeline","source":"prnewswire.com","summary":"The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Di","headline":"The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal ant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBGSk1IS3VFbmVtLUM0ZS1mVkNrb2RleTE3VzkyTjA4SnlUUmpxTEFramJCdTJZSERmQjZwVVprTmo4LUZhRURzVjNTTWtvTngwdWtZMFdWTDB5VTA4eE9Ram9ScUxfXzRyS3c?oc=5","date":"2024-06-28","type":"pipeline","source":"The Pharma Letter","summary":"ILTOO Pharma | Biotechnology | The Pharmaletter - The Pharma Letter","headline":"ILTOO Pharma | Biotechnology | The Pharmaletter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNMzNnTURzU052c0ZJYkFRVzdWZUJuV0VLVEh3UWpjb1JJNjRkMDBvVjdPbV80eWpGeWxwdHBKUHU5ZlF5OGRRWi1OQVFncDVTYjRSQlJ0c2RFczhCYTN6WWZvWHpvZFBVV2ZIemdnTjFpS0VGMVlxQUR3SkQ0Ny1VdDctd0dlbFlMQXF5OWxfNGdPQ0RNSllOcmRnazhHNFdtR3RuQ05jR0RIX2c5VkE?oc=5","date":"2023-05-10","type":"pipeline","source":"AFM Téléthon","summary":"Licence agreement for the development of a treatment for Amyotrophic Lateral Sclerosis (ALS) - AFM Téléthon","headline":"Licence agreement for the development of a treatment for Amyotrophic Lateral Sclerosis (ALS) - AFM Téléthon","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}